SPYRE THERAPEUTICS, INC.
9.99%
9,016,702
1636282
Apr 15, 2026
Apr 20, 2026, 06:00 PM
Reporting Persons (4)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Peter Harwin | Individual | 9.99% | 9,016,702 | 520,361 | 8,496,341 |
| Tomas Kiselak | Individual | 9.99% | 9,016,702 | 520,361 | 8,496,341 |
| Fairmount Funds Management LLC | Investment Adviser | 9.09% | 8,184,941 | 0 | 8,184,941 |
| Fairmount Healthcare Fund II L.P. | Partnership | 9.09% | 8,184,941 | 0 | 8,184,941 |
Disclosure Items (4)
Common Stock, $0.0001 par value
SPYRE THERAPEUTICS, INC.
221 Crescent Street, Waltham, MA, 02453
The information in rows 11 and 13 of each of the cover pages (including the explanatory note in the "Comments") of this Amendment No. 6 is incorporated by reference herein. Together, the Reporting Persons' securities include (i) 4,830,177 shares of Common Stock, (ii) 228,646 shares of Common Stock issuable upon the exercise of options held by the Reporting Persons that are currently exercisable or will be exercisable within 60 days of the date of this filing and, (iii) 3,912,800 shares of Common Stock issuable upon conversion of 97,820 shares of Series A Preferred Stock subject to the 9.99% beneficial ownership limitation applied to all of the securities owned by the Reporting Persons. The securities exclude shares of Common Stock issuable upon conversion of 248,225 shares of Series A Preferred Stock and 16,667 shares of Series B Preferred Stock held directly by Fund II in excess of the beneficial ownership limitation of 9.99%.
The information in rows 7 through 10 of each of the cover pages of this Amendment No. 6 is incorporated by reference herein.
None
Lock-Up Agreement In connection with the Company's underwritten public offering of common stock that closed on April 16, 2026, the Reporting Persons entered into a customary lock-up letter agreement (the "Lock-Up Agreement") with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC as the representatives (the "Representatives") of the underwriters to an underwriting agreement with the Company. Pursuant to the Lock-Up Agreement, the Reporting Persons agreed to refrain from selling shares of the Company's securities without the consent of the Representatives, and other customary lock-up conditions, for a period of 60 days from the date of the Company's final prospectus supplement related to the offering. The Reporting Persons did not purchase any securities of the Company or otherwise participate in the offering. The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the form of the Lock-Up Agreement, which is filed as Exhibit 99.2 to this Schedule 13D and incorporated herein by reference.
99.1 Joint Filing Agreement 99.1 (incorporated by reference to Exhibit 99.1 of the Reporting Persons' Schedule 13D filed with the SEC on October 17, 2025). 99.2 Lock-Up Agreement (incorporated by reference to Exhibit A to the Underwriting Agreement filed as Exhibit 1.1 of the Company's Form 8-K filed with the SEC on April 16, 2026).